European Society of Contraception Statement on Contraception in Obese Women

被引：30

作者：

Merki-Feld, Gabriele S. ^{[1
]}

Skouby, Sven ^{[2
]}

Serfaty, David ^{[3
]}

Lech, Medard ^{[4
]}

Bitzer, Johannes ^{[5
]}

Crosignani, Pier Giorgio ^{[6
]}

Cagnacci, Angelo ^{[7
]}

Sitruk-Ware, Regine ^{[8
]}

机构：

[1] Univ Zurich Hosp, Clin Gynecol & Obstet, Dept Reprod Endocrinol, Zurich, Switzerland

[2] Univ Copenhagen, Dept Obstet & Gynecol, Endocrinol & Reprod Unit, DK-1168 Copenhagen, Denmark

[3] Francophone Soc Contracept, Paris, France

[4] Fertil & Steril Res Ctr, Warsaw, Poland

[5] Univ Basel Hosp, Dept Obstet & Gynecol, CH-4031 Basel, Switzerland

[6] IRCC Ca Grande Fdn Maggiore Policlin Hosp, Sci Direct, Milan, Italy

[7] Policlin, Modena, Italy

[8] Populat Council, New York, NY 10021 USA

来源：

EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE | 2015年 / 20卷 / 01期

关键词：

Hormonal contraception; Thromboembolic risk; Efficacy; Obesity; Weight; Contraceptive failure; Progestin-only contraception; Depo-medroxyprogesterone; DEPOT-MEDROXYPROGESTERONE ACETATE; DESOGESTREL-ONLY CONTRACEPTION; ORAL-CONTRACEPTIVES; EMERGENCY CONTRACEPTION; VENOUS THROMBOEMBOLISM; INTRAUTERINE SYSTEM; ULIPRISTAL ACETATE; ETONOGESTREL IMPLANT; ACTIVE SURVEILLANCE; HEADACHE FREQUENCY;

D O I：

10.3109/13625187.2014.960561

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The obesity 'epidemic' continues to increase, mostly but not only in developed countries. As overweight and obese women are at an increased risk for venous thromboembolism (VTE) at baseline and at a much higher risk during pregnancy, it is essential to help these women to plan pregnancies carefully and to use contraceptives with a positive ratio of benefits versus risks. The Expert Group on hormonal and molecular contraception of the European Society of Contraception convened to review the existing evidence and propose recommendations to the prescribers in line with most recent studies and with the Medical Eligibility Criteria of the World Health Organisation.

引用

页码：19 / 28

页数：10

共 74 条

[1] Low-dose contraceptive estrogen-progestin and coronary artery atherosclerosis of monkeys [J].

Adams, MR ;

Anthony, MS ;

Manning, JM ;

Golden, DL ;

Parks, JS .

OBSTETRICS AND GYNECOLOGY, 2000, 96 (02) :250-255

[2] Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol [J].

Anderson, FD ;

Gibbons, W ;

Portman, D .

CONTRACEPTION, 2006, 73 (03) :229-234

[3]

[Anonymous], BMJ

[4]

[Anonymous], 2011, 111022V2 CHC CVD

[5]

[Anonymous], 2014, LANCET

[6]

[Anonymous], COCHRANE DATABASE SY

[7] Use of the levonorgestrel-releasing intrauterine system in women with endometriosis, chronic pelvic pain and dysmenorrhea [J].

Bahamondes, Luis ;

Petta, Carlos A. ;

Fernandes, Arlete ;

Monteiro, Ilza .

CONTRACEPTION, 2007, 75 (06) :S134-S139

[8] The effects of two progestogen-only pills containing either desogestrel (75 μg/day) or levonorgestrel (30 μg/day) on lipid metabolism [J].

Barkfeldt, J ;

Virkkunen, A ;

Dieben, T .

CONTRACEPTION, 2001, 64 (05) :295-299

[9] Effect of Implanon® and Norplant® subdermal contraceptive implants on serum lipids-a randomized comparative study [J].

Biswas, A ;

Viegas, OAC ;

Roy, AC .

CONTRACEPTION, 2003, 68 (03) :189-193

[10] The New Extended-Cycle Levonorgestrel-Ethinyl Estradiol Oral Contraceptives [J].

Bonnema, Rachel A. ;

Spencer, Abby L. .

CLINICAL MEDICINE INSIGHTS-REPRODUCTIVE HEALTH, 2011, 5 :49-54

← 1 2 3 4 5 6 7 8 →